Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Net Income (2016 - 2025)

Historic Net Income for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to -$1.2 million.

  • Ernexa Therapeutics' Net Income rose 9533.9% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.4 million, marking a year-over-year increase of 5913.92%. This contributed to the annual value of -$44.6 million for FY2024, which is 10564.43% down from last year.
  • Per Ernexa Therapeutics' latest filing, its Net Income stood at -$1.2 million for Q3 2025, which was up 9533.9% from -$3.1 million recorded in Q2 2025.
  • Ernexa Therapeutics' Net Income's 5-year high stood at -$1.2 million during Q3 2025, with a 5-year trough of -$86.0 million in Q3 2021.
  • For the 5-year period, Ernexa Therapeutics' Net Income averaged around -$12.2 million, with its median value being -$5.8 million (2024).
  • In the last 5 years, Ernexa Therapeutics' Net Income tumbled by 570594.19% in 2021 and then soared by 9533.9% in 2025.
  • Ernexa Therapeutics' Net Income (Quarter) stood at -$86.0 million in 2021, then surged by 94.78% to -$4.5 million in 2022, then tumbled by 37.07% to -$6.2 million in 2023, then grew by 6.08% to -$5.8 million in 2024, then soared by 78.54% to -$1.2 million in 2025.
  • Its Net Income stands at -$1.2 million for Q3 2025, versus -$3.1 million for Q2 2025 and -$8.2 million for Q1 2025.